Novo Nordisk registers Phase 3 obesity trial in Japan; new CagriSema switch study
Novo Nordisk posted two new phase 3 trial registrations this week, one for NNC0487-0111 in Japanese patients with excess weight and one testing a switch from semaglutide to CagriSema.
Novo Nordisk registered two new phase 3 studies this week.
- Novo Nordisk registered "AMAZE 10," a phase 3 trial of once-weekly subcutaneous NNC0487-0111 in Japanese participants with overweight or obesity, now recruiting. The study is designed to enroll 400 participants and its primary outcome is relative change in body weight from baseline to week 84.1
- Novo Nordisk registered a phase 3 study on switching participants with type 2 diabetes from semaglutide to CagriSema, not yet recruiting. The purpose is to look at the safety and tolerability of switching from semaglutide to CagriSema, and participants will be in the study for about 6 months.2 Its primary outcome is the number of treatment emergent adverse events from baseline to week 16.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.